Evaluation of Targeted Mass Cholera Vaccination Strategies in Bangladesh: A Demonstration of a New Cost-Effectiveness Calculator

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65–74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750–17 100). Vaccination of high-risk individuals aged 65–74 years was cost-saving and extension to medium-risk individuals aged 65–74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

Download Full-text

Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting

BMC Medicine ◽

10.1186/s12916-018-1134-3 ◽

2018 ◽

Vol 16 (1) ◽

Cited By ~ 10

Author(s):

P. Bruijning-Verhagen ◽

J. A. P. van Dongen ◽

J. D. M. Verberk ◽

R. Pijnacker ◽

R. D. van Gaalen ◽

...

Keyword(s):

Cost Effectiveness ◽

High Income ◽

Benefit Analysis ◽

Rotavirus Vaccination ◽

Endemic Setting ◽

Vaccination Strategies ◽

Risk Benefit Analysis

Download Full-text

Oral cholera vaccination strategies involving 2 doses would be cost effective in Bangladesh

PharmacoEconomics & Outcomes News ◽

10.1007/s40274-021-08109-2 ◽

2021 ◽

Vol 889 (1) ◽

pp. 21-21

Keyword(s):

Cost Effective ◽

Vaccination Strategies ◽

Cholera Vaccination

Download Full-text

Acceptability of vaccination against HIV: A mapping of Togolese people’s positions

Journal of Health Psychology ◽

10.1177/1359105316639440 ◽

2016 ◽

Vol 23 (6) ◽

pp. 800-806 ◽

Cited By ~ 3

Author(s):

Lonzozou Kpanake ◽

Sadji Gbandey ◽

Paul Clay Sorum ◽

Etienne Mullet

Keyword(s):

Cost Effectiveness ◽

Vaccine Effectiveness ◽

Hiv Vaccine ◽

Cost Effectiveness Ratio ◽

Vaccine Cost ◽

Perceived Severity ◽

Aids Vaccine ◽

Vaccination Strategies ◽

Five Factors ◽

To Receive

In anticipation of a future HIV vaccine, we mapped the different personal positions regarding HIV vaccination of people in Togo. In early 2014, 363 adults indicated their willingness to receive a future HIV vaccine under different conditions varying as a function of five factors: perceived susceptibility to HIV, vaccine effectiveness, perceived severity of AIDS, vaccine cost, and family’s influence. We found five qualitatively different positions: unconditional acceptance (49%), depends on cost/effectiveness ratio (20%), depends on cost (18%), total indecision (10%), and complete reluctance (3%). Accordingly, HIV vaccination strategies in Togo and elsewhere in Africa need to be multifaceted and tailored.

Download Full-text